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Lymphocytes provide optimal responses against
pathogens with minimal inflammatory pathology.
However, the intrinsic mechanisms regulating these
responses are unknown. Here, we report that dele-
tion of both transcription factors Egr2 and Egr3 in
lymphocytes resulted in a lethal autoimmune syn-
drome with excessive serum proinflammatory cyto-
kines but also impaired antigen receptor-induced
proliferation of B and T cells. Egr2- and Egr3-defec-
tive B and T cells had hyperactive signal transducer
and activator of transcription-1 (STAT1) and STAT3
while antigen receptor-induced activation of tran-
scription factor AP-1 was severely impaired. We
discovered that Egr2 and/or Egr3 directly induced
expression of suppressor of cytokine signaling-1
(SOCS1) and SOCS3, inhibitors of STAT1 and
STAT3, and also blocked the function of Batf, an
AP-1 inhibitor, in B and T cells. Thus, Egr2 and Egr3
regulate B and T cell function in adaptive immune
responses and homeostasis by promoting antigen
receptor signaling and controlling inflammation.
INTRODUCTION
The immune system is finely balanced between providing
immune responses against infectious pathogens while remain-
ing tolerant to self-antigen (Goodnow et al., 2010; Kitaura
et al., 2007; Schwartz, 2003; Sprent and Surh, 2011; von
Boehmer and Melchers, 2010). In optimal immune responses,
antigen and costimulatory molecules from activated antigen
presenting cells (APCs) or helper T cells induce strong mitogenic
signals in naive T or B cells, leading to proliferation and differen-
tiation of effector cells; yet these same stimuli also induce
suppressors, such as induced regulatory T (iTreg) cells, to
prevent excessive immune pathology. Under homeostatic con-
ditions, such as interaction with self-antigens and/or cytokines,
T and B cells either do not respond or undergo homeostatic
proliferation (Sprent and Surh, 2011; von Boehmer and Melch-ers, 2010). Recent studies suggest that the control of responses
to self-antigen under homeostatic conditions is an active
process involving induction of anergic molecules, such as E3
ubiquitin ligases and negative regulators of T cell receptor
signaling (Bandyopadhyay et al., 2007; King et al., 2008; Macia´n
et al., 2002; MacDonald et al., 2011; Puga et al., 2008; Thomas
et al., 2007). These molecules can effectively reduce activation
of MAP kinase and AP-1 transcription factor, the hallmarks of
tolerant T cells (Schwartz, 2003). In addition to the control of
antigen receptor signaling, the regulation of the concerted action
of pro- and anti-inflammatory cytokines is also important for
the maintenance of self-tolerance (Davey et al., 2005; MacDon-
ald et al., 2011; Tamiya et al., 2011). Deficiency in suppressor of
cytokine signaling-1 (SOCS1) or SOCS3, suppressors of
signal transducer and activator of transcription 1 (STAT1)- and
STAT3-mediated proinflammatory cytokine signaling, results in
the development of severe inflammatory autoimmune syn-
dromes and/or renders the mice susceptible to the induction of
autoimmune diseases (Chong et al., 2005; Croker et al., 2004;
Davey et al., 2005; Marine et al., 1999; Tamiya et al., 2011).
Egr2 and Egr3 are zinc-finger transcription factors of the early
growth response gene (Egr) family (O’Donovan et al., 1999) that
have critical functions in hindbrain development and myelination
of the peripheral nervous system (Topilko et al., 1994; Tourtel-
lotte and Milbrandt, 1998) and are also involved in the develop-
ment of T and/or B cells (Lazarevic et al., 2009; Li et al., 2011;
Xi et al., 2006). The involvement of Egr2 and Egr3 in the regula-
tion of T cell tolerance was first suggested by the induction of
their expression in tolerant B and T cells (Anderson et al.,
2006; Harris et al., 2004; Safford et al., 2005). T cell lines overex-
pressing Egr2 or Egr3 show an upregulation of E3-ligase Cbl-b
and reduced production of interleukin-2 (IL-2), suggesting that
Egr2 and Egr3 are important for the maintenance of T cell toler-
ance by negatively regulating T cell activation (Harris et al., 2004;
Safford et al., 2005). Previously, we found that Egr2 is expressed
in CD44hi effector phenotype T cells under homeostatic condi-
tions and a defect in Egr2 in T cells results in accumulation of
interferon-g (IFN-g)- and IL-17-producing CD44hiCD4 T cells,
leading to the development of a lupus-like syndrome in later
life (Zhu et al., 2008). However, Egr2-deficient T cells are not
hyperproliferative in response to primary T cell receptor (TCR)
stimulation (Zhu et al., 2008). This normal response to TCR
engagement could be due to functional compensation by Egr3.Immunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc. 685
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Figure 1. Mice Lacking Egr2 and Egr3 in B
and T cells Develop a Severe Systemic Auto-
immune Syndrome
(A) Pathological analysis of lung, liver, and kidney
sections from 3-month-old mice showing
lymphocytic infiltration in CD2-Egr2/Egr3/
(K2-3) tissues (hematoxylin and eosin [HE]).
(B) Serum Ig in 3-month-old K2-3 and wild-type
(WT) mice.
(C) Self-reactive antibodies and urine protein levels
in K2-3 and WT mice at the indicated ages.
(D) Glomerular Ig deposits in 3-month-old K2-3
mice (Texas red-labeled anti-mouse Ig).
(E) Absolute numbers of splenic B and T cells in
8-week-old mice.
(F) Surface marker expression on splenic B and
T cells from 8-week-oldWT and K2-3mice. Data in
(B), (C), and (E) are the mean ± standard deviation
from four mice; the remaining data are represen-
tative of four mice. NS, not significant; *p < 0.05
(unpaired Student’s t test).
Immunity
Egr2 and Egr3 Regulate Function of B and T CellsHere, we report that mice with deficiency of both Egr2 and
Egr3 in B and T cells developed a lethal and early-onset systemic
inflammatory autoimmune syndrome. However, IL-2 production
and proliferation of B and T cells in response to mitogenic
antigen receptor stimulation in vitro were severely impaired as
a result of a defect in AP-1 activity. Our results demonstrate
that Egr2 and Egr3 reciprocally control the inflammatory
responses and antigen receptor signaling of B and T cells in
both homeostasis and antigen receptor-mediated immune
responses.
RESULTS
Deficiency in Egr2 and Egr3 in B and T cells Results
in Severe Autoimmune Diseases
Previously, we found the development of systemic autoimmunity
in CD2-specific Egr2-deficient (CD2-Egr2/) mice in later life,
but B and T cell responses to antigen receptor stimulation
in vitro were unchanged (Zhu et al., 2008), although there were
no autoimmune symptoms found in Egr3/ mice (data not
shown). To explore the functions of Egr2 and Egr3 in lympho-
cytes, we interbred Egr3/ and CD2-Egr2/ mice to establish
mice (CD2-Egr2/Egr3/) with defects in both Egr2 and 3 in T
and B cells (Figures S1A and S1B available online). In our686 Immunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc.previous study, we observed incomplete
excision of the floxed Egr2 gene in B cells
from CD2-specificEgr2/ mice due to
some of these mice being heterozygous
for the cre-transgene (Zhu et al., 2008).
However, in CD2-Egr2/Egr3/ mice
homozygous for the cre-transgene, the
Egr2 gene was completely deleted
(Figures S1A and S1B). Total numbers of
thymocytes and bone marrow B cells in
CD2-Egr2/Egr3/mice were reduced
(Figures S2A–S2D). However, the
numbers of the major subpopulations of
mature T and B lymphocytes in the lymphnodes and spleen of 5-week-old CD2-Egr2/Egr3/ mice
were similar to age-matched wild-type mice and the develop-
ment of Treg cells was unchanged (Figures S3A and S2A).
Furthermore, the function of peripheral Treg cells from 5-week-
old CD2-Egr2/Egr3/ mice in suppressing the activation of
naive CD4+ T cells from wild-type mice was also normal (Fig-
ure S3B). However, at 2 months of age, both male and female
CD2-Egr2/Egr3/mice developed a severe systemic autoim-
mune syndrome with lymphocytic infiltration in multiple organs,
high levels of anti-self antibodies and glomerulonephritis
(Figures 1A–1D; Figure S3C). Splenomegaly and super-enlarged
lymph nodes were among the most prominent features of sick
CD2-Egr2/Egr3/ mice with increased numbers of highly
activated B and T cells (Figures 1E and 1F; Figure S4A). The
CD2-Egr2/Egr3/ mice became moribund at 8 months of
age because of multiorgan inflammation, which was associated
with high levels of serum inflammatory cytokines, including IL-3,
IL-6, IL-10, IL-17A, and IL-17F, granulocyte macrophage colony
stimulating factor (GM-CSF), and IFN-g, and large numbers of
IL-17- and IFN-g-producing CD4+ T cells (Figures 2A and 2B;
Figures S3D and S4B). Interestingly, although B and T cells
from sick mice displayed hyperactivated phenotypes, their
proliferation and production of IL-2 were severely impaired
in response to antigen receptor stimulation in vitro (Figures
g
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Figure 2. Egr2 and Egr3 Control the Homeo-
stasis of, and Production of Inflammatory
Cytokines by, B and T Cells
(A) Serum cytokine levels in 3-month-old wild-type
(WT) and CD2-Egr2/Egr3/ (K2-3) mice.
(B) IL-17A- and IFN-g-producing CD4+ T cells from
spleens of 8-week-old mice.
(C and D) Proliferation of CD4+ T (C) and B cells (D)
from 3-month-old mice, as measured by 3H-TdR
incorporation, after in vitro stimulation with anti-
CD3 and anti-CD28, for CD4+ T cells, or anti-IgM,
for B cells, for 3 days.
(E) Production of IL-2 by CD4+ T cells after in vitro
stimulation with anti-CD3 and anti-CD28 for 24 hr.
(F and G) Naive CD4 or B cells from spleens of
4-week-old WT and K2-3 mice were adoptively
transferred into Rag2/ mice at 1 3 106 cells/per
mouse. Six weeks after transfer, the spleen and
lymph nodes were harvested and surface marker
expression (F), cell numbers and serum immuno-
globulin and cytokines (G) were analyzed. Data in
(A), (C)–(E), and G are the mean ± standard devi-
ation from four mice; the remaining data are
representative of two independent experiments.
NS, not significant; *p < 0.05, **p < 0.01, and
***p < 0.005 (unpaired Student’s t test).
Immunity
Egr2 and Egr3 Regulate Function of B and T Cells2C–2E), suggesting that the hyperactivated phenotypes were
not due to reduced antigen receptor activation thresholds.
To determine whether these functions of Egr2 and Egr3 were
cell intrinsic, we transferred either resting B or naive CD4+
T cells from 4-week-old wild-type or CD2-Egr2/Egr3/
mice, before the onset of lymphadenopathy and the signs of
autoimmunity, into Rag2/ mice (Figure 1C; Figures S3C and
S3D). Six weeks after transfer, the B and T cells from wild-type
mice largely displayed a resting phenotype in Rag2/ recipient
mice, whereas Egr2- and Egr3-deficient B and CD4+ T cells in
Rag2/ recipient mice were activated and produced high levels
of serum Ig and cytokines, respectively (Figures 2F and 2G). A
similar activated phenotype on Egr2- and Egr3-deficient, but
not wild-type, CD4+ T and B cells was observed in Rag2/
recipient mice, which received a 50:50 mixture of lymphocytes
from 4-week-old CD45.1+ wild-type and CD45.2+ CD2-
Egr2/Egr3/ mice (Figure S4D). Furthermore, the percent-
ages of Egr2- and Egr3-deficient B and T cells were increased
6 weeks after transfer with 62% CD2-Egr2/Egr3/ versus
38% wild-type CD4+ T cells, and 71% CD2-Egr2/Egr3/
versus 29% wild-type B cells. Thus, Egr2 and Egr3 regulate
the homeostasis of both B and T cells in a cell-intrinsic manner.Immunity 37, 685–696,Egr2 and Egr3 Are Required for
Antigen Receptor-Induced B and
T cell Proliferation and the Control
of Inflammatory Cytokine
Production
Egr2 and Egr3 have been found to
negatively regulate T cell activation
in vitro (Harris et al., 2004; Safford et al.,
2005). To confirm this, we isolated naive
B and T cells from spleens of CD2-
Egr2/Egr3/ mice before the onset of
autoimmune symptoms were stimulated with anti-IgM, or anti-
CD3 and anti-CD28, respectively. To our surprise, defects in
Egr2 and Egr3 resulted in severely impaired B and T cell
activation as demonstrated by defects in proliferation and
production of IL-2 (Figures 3A–3C), whereas the proliferation of
B and T cells with a single defect in either Egr2 or Egr3
was normal (Figure S5). Conversely, B and CD4+ T cells consti-
tutively expressing Egr2, from CD2-specific Egr2 transgenic
(Egr2 cTg) mice (Li et al., 2011), showed enhanced proliferative
responses and increased IL-2 production in response to antigen
receptor stimulation (Figures 3A–3C; Figure S5). The impaired
proliferative responses of Egr2- and Egr3-deficient B and
T cells were not due to increased cell death given that apo-
ptosis was normal (Figure S5). Our results demonstrate
that Egr2 and Egr3 are required for efficient proliferation of naive
B and T cells in response to mitogenic antigen receptor
stimulation.
In contrast to the defects in proliferation and IL-2 expression,
mitogenic antigen receptor stimulation induced high amounts of
expression of inflammatory cytokines, including IL-1b (Fig-
ure S4C), IL-4, IL-17A, IL-21, GM-CSF, and IFN-g in CD4+
T cells and IL-6 in B cells (Figures 3C and 3D), which isOctober 19, 2012 ª2012 Elsevier Inc. 687
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Figure 3. Lack of Egr2 and Egr3 Results in
Impaired Responses to Antigen Receptor
Stimulation, and Excessive Production of
Inflammatory Cytokines In Vitro
(A) BrdU incorporation by naive splenic CD4+
T cells from 4-week-old wild-type (WT), CD2-
Egr2/Egr3/ (K2-3) and Egr2 cTg (Tg) mice
after stimulation in vitro for 3 days with anti-CD3
and anti-CD28.
(B) Proliferation of naive CD4+ T and B cells, as
measured by 3H-TdR incorporation, after in vitro
stimulation with anti-CD3 and anti-CD28, for CD4+
T cells or anti-IgM, for B cells, for 3 days.
(C) mRNA expression levels of cytokines in naive
CD4+ T cells after stimulation with anti-CD3 and
anti-CD28 for 16 hr as measured by RT-PCR. Note
that the y axes in the IFN-g and GM-CSF plots
have been broken.
(D) mRNA expression of IL-6 in resting B cells after
stimulation with anti-IgM for 16 hr as measured by
RT-PCR.
(E) Expression of Egr2, Egr3, and cytokines in
CD4+ T cells from WT mice after transfection with
siRNAs against Egr2 and Egr3.
(F) Proliferation of CD4+ T and B cells from WT
mice after transfection with siRNAs against Egr2
and Egr3. Results in (C)–(E) are presented relative
to the expression of b-actin mRNA. Data are
representative of three (A–D) or two (E and F)
independent experiments. *p < 0.05, **p < 0.01
and ***p < 0.005 (unpaired Student’s t test).
Immunity
Egr2 and Egr3 Regulate Function of B and T Cellsconsistent with the inflammatory cytokines detected in the
serum of CD2-Egr2/Egr3/ mice (Figure 2). Conversely, B
and CD4+ T cells overexpressing Egr2, from Egr2 transgenic
(Egr2 cTg) mice, showed reduced inflammatory cytokine
production (Figures 3C and 3D). To determine whether the
reduced antigen receptor-induced proliferation of lymphocytes
from CD2-Egr2/Egr3/ mice is due to the inflammatory
environment, we isolated CD45.1+ wild-type and CD45.2+
Egr2/Egr3/ B and CD4+ T cells from the same Rag2/
recipient mouse 6 weeks after transfer for proliferative re-
sponses in vitro. Egr2- and Egr3 -deficient, but not wild-type,
B and CD4+ T cells displayed defective antigen receptor-driven
proliferation (Figure S4E), again suggesting again an intrinsic
role for Egr2 and Egr3 in the regulation of antigen receptor-
induced proliferation. To exclude the possibility that the impaired
responses to antigen receptor stimulation were due to alter-688 Immunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc.ations in lymphocyte development, we
silenced Egr2 and Egr3 in wild-type
CD4+ and B cells (Figure S1C, Figure 3E).
The reduction of Egr2 and Egr3 expres-
sion resulted in defective proliferation
and IL-2 production, but increased pro-
duction of inflammatory cytokines, in
response to antigen receptor stimulation
(Figures 3E and 3F), consistent with the
alterations seen in Egr2- and Egr3-
deficient CD4+ T and B cells. Our results
demonstrate that Egr2 and Egr3 are
required for both optimal B and T cellproliferation and the control of inflammatory cytokine
expression.
Egr2 and/or Egr3 Control STAT1 and STAT3 Activation
and Regulate the Expression of SOCS1 and SOCS3
The impaired proliferation of, and IL-2 production by, CD4+
T cells after antigen receptor stimulation indicated that the
excessive production of inflammatory cytokines by Egr2- and
Egr3-deficient B and T cells was not due to hyperactivation of
antigen receptor signaling pathways. We therefore analyzed
the major cytokine signaling pathways in B and T cells. We
found hyperactivation of STAT3 in B and T cells in the lymph
nodes of 3-month-old CD2-Egr2/Egr3/ mice (Figure 4A).
Next, we examined the activation of STAT1, STAT3, and
STAT5 in naive B and T cells isolated from 4-week-old CD2-
Egr2/Egr3/ mice. We found that B and CD4+ T cells from
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Figure 4. Dysregulation of STAT1 and
STAT3 Pathways in Egr2- and Egr3-deficient
B and T Cells
(A) Phosphorylation of STAT3 in B and T cells in
lymph nodes from wild-type (WT) and CD2-
Egr2/Egr3/ (K2-3) mice at 3 months of age.
(B andC) Phosphorylation of STAT1 and STAT3 (B)
and expression of SOCS1, SOCS2, and SOCS3
(C) in naive CD4+ T or B cells from 4-week-old WT
and K2-3 mice after stimulation with anti-CD3 and
anti-CD28 antibodies, for CD4, or anti-IgM, for
B cells for 6 hr.
(D) Expression of cytokines and SOCS3 or SOCS1
in CD4+ T cells from K2-3 mice after transduction
with SOCS1- or SOCS3-lentivirus-IRES-GFP.
After lentivirus infection, CD4 T cells were stimu-
lated with anti-CD3 and anti-CD28 for 16 hr. The
transduced cells were isolated by cell sorting for
GFP-positive cells. Lentivirus-IRES-GFP served
as a control.
(E) Phosphorylation of STAT3 in Egr2- and Egr3-
deficient CD4+ T cells transduced with SOCS3-
lentivirus.
(F) Binding of Egr2 to the proximal regions of the
SOCS1 and SOCS3 promoters. CD4 T cells from
Egr2 transgenic mice (Egr2cTg) were stimulated
with anti-CD3 and anti-CD28 for 3 hr and used in a
chromatin immunoprecipitation assay (CHIP) with
primers flanking Egr binding sites in the promoters
of SOCS1, SOCS3, and Nab. Total input DNA and
anti-H3 precipitates served as positive controls
and anti-Ig precipitates as a negative control.
(G) Activity of the SOCS1 and SOCS3 promoters.
Control pGL3 (p) or SOCS1 (S1) or SOCS3 (S3)
reporter gene constructs were transfected into
HEK293 cells in the presence of Egr2 (E) or GFP
control (G). Luciferase activity was measured 24 hr
after transfection. Results in (C) and (D) are pre-
sented relative to the expression of b-actin mRNA.
Data are representative of three (A–C and G) or
two (D–F) independent experiments. *p < 0.05
(unpaired Student’s t test).
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Egr2 and Egr3 Regulate Function of B and T CellsCD2-Egr2/Egr3/ mice showed increased activation of
STAT1 and STAT3, but not STAT5 (data not shown), in response
to antigen receptor stimulation in vitro, compared with B and
T cells from wild-type mice (Figure 4B). Previously, we and
others found that SOCS1 and SOCS3, suppressors of STAT1
and STAT3 activation, can be induced in T cells by TCR stimu-
lation (Anderson et al., 2003; Diehl et al., 2000). To investigate
whether Egr2 and/or Egr3 can regulate expression of SOCS
molecules, we analyzed the expression of SOCS1, SOCS2,
and SOCS3 in naive CD4+ T and B cells from 4-week-old mice
after antigen receptor stimulation. The expression of SOCS1
and SOCS3, but not SOCS2, was highly induced in B and
T cells from Egr2 cTg mice whereas, conversely, deficiency in
Egr2 and Egr3 resulted in defective expression of SOCS1 and
SOCS3 (Figure 4C). To determine the importance of impaired
expression of SOCS1 and SOCS3 to the phenotypes observed
in Egr2- and Egr3-deficient CD4+ T cells, we transduced
SOCS1 or SOCS3 into naive Egr2- and Egr3-deficient CD4+
T cells by using SOCS-encoding lentiviruses. Previously, wedemonstrated that the SOCS3 lentivirus can efficiently suppress
activation of STAT3 (Miao et al., 2006). Indeed, expression of
SOCS1 reduced IFN-g production in Egr2- and Egr3-deficient
CD4+ T cells, whereas SOCS3 suppressed STAT3 activation
and production of IL-17A (Figures 4D and 4E). Next, we analyzed
the proximal promoters of SOCS1 and SOCS3 for potential
Egr binding sites. We discovered a number of potential Egr2
binding sites in the conserved intergenic elements of the
SOCS3 locus and the promoters of the SOCS1 and SOCS3,
but not SOCS2, genes (Figure S6). Chromatin immunoprecipita-
tion assays (ChIPs) demonstrated that Egr2 directly interacted
with the SOCS1 and SOCS3 promoters and a conserved inter-
genic element in the SOCS3 locus (Figure 4F). To determine
whether Egr2 can trans-activate the SOCS1 and SOCS3
promoters, we cloned the proximal promoter regions of
SOCS1 and SOCS3 into basic luciferase reporter constructs
and measured the promoter activity in the presence of Egr2.
The results showed that Egr2 induced increased SOCS1 and
SOCS3 promoter activity (Figure 4G). Thus, we have discoveredImmunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc. 689
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Figure 5. Lack of Egr2 and Egr3 Selectively
Impairs AP-1 Activation in B and T Cells
(A) Naive CD4+ T and resting B cells were stimu-
lated with anti-CD3 and anti-CD28 or anti-IgM.
Then, the cytoplasmic extracts were analyzed for
Erk phosphorylation, using anti-phospho-Erk
antibody, while the nuclear extracts were analyzed
for the activation of AP-1, NF-kB and NFAT by
EMSA using their respective consensus DNA
probes. The arrows indicate the alternative
complex in CD2-Egr2/Egr3/ (K2-3) samples
that bound to the AP-1 DNA probe. B. Quantitation
of AP-1 band intensities on a phosphorimager
after normalization relative to the intensity of an
internal loading control, SP1. C. AP-1 reporter
gene assay in CD4 cells from wild-type and K2-3
mice. After transfection with an AP-1 reporter gene
(AP-1-Luc), CD4+ T cells were stimulated with
anti-CD3 and anti-CD28 before AP-1 activity was
assessed by luciferase assay. D. AP-1 reporter
gene assay in wild-type CD4 cells after co-trans-
fection with siRNAs against Egr2 and 3, and AP-1-
Luc. The transfected cells were stimulated with
anti-CD3 and anti-CD28 before AP-1 activity
was assessed by luciferase assay. E. EMSA
supershift analysis, using the indicated antibodies,
of nuclear extracts from CD4+ T cells stimulated
with anti-CD3 and anti-CD28 using the consensus
AP-1 DNA probe. Data are representative of
three (A), (B), (D) or two (C), and (E) independent
experiments. *p < 0.05, **p < 0.01 (unpaired
student’s t test).
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Egr2 and Egr3 Regulate Function of B and T Cellsa function of Egr2 and/or Egr3: direct regulation of SOCS1 and
SOCS3 expression that may be important to control the activa-
tion of STAT1- and STAT3-mediated cytokine signaling in B and
T cells in both homeostatic conditions and mitogenic antigen
receptor-mediated responses.
Egr2 and Egr3 Are Required for the Activation of the
AP-1 Transcription Factor in Naive B and T cells after
Antigen Receptor Signaling
In contrast to the increased activation of STAT1 and STAT3
and excessive production of proinflammatory cytokines, the
proliferation of, and production of IL-2 by, naive B and/or
T cells from CD2-Egr2/Egr3/ mice was severely impaired
in response to mitogenic antigen receptor stimulation (Figure 3).
Therefore, we next examined the antigen receptor signaling690 Immunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc.pathways in naive B and CD4+ T cells iso-
lated from CD2-Egr2/Egr3/ mice
before the onset of autoimmune disease.
The activation of most of the intracellular
signaling molecules, including MAP
kinases, demonstrated by phosphoryla-
tion of Erk, and the transcription factors
NF-kB and NFAT in naive B and CD4+
T cells from CD2-Egr2/Egr3/ and
Egr2 cTg mice in response to antigen
receptor ligation in vitro was not altered
compared with B and T cells from wild-
type controls (Figures 5A and 5B).However, the activation of AP-1 was severely impaired in
Egr2- and Egr3-deficient CD4+ T and B cells (Figures 5A and
5B). Conversely, overexpression of Egr2 increased AP-1 DNA
binding activity in CD4+ T and B cells (Figures 5A and 5B).
To further confirm the importance of Egr2 and Egr3 for
efficient AP-1 activation, we carried out an AP-1 reporter
gene assay. Consistent with the DNA binding results, anti-
CD3 and anti-CD28 induced AP-1 reporter gene activity was
reduced in CD4+ T cells from CD2-Egr2/Egr3/ mice, as
well as in wild-type CD4+ T cells after silencing Egr2 and Egr3
(Figures 5C and 5D). These results demonstrate that Egr2 and
Egr3 are required for antigen receptor-induced AP-1 activation,
which is essential for the production of IL-2 and cell cycle
progression in T and B cells (Foletta et al., 1998; Rinco´n and
Flavell, 1994).
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Figure 6. Egr2 Interacts with Batf and
Blocks Its Binding to the AP-1 DNA
Consensus Probe
(A–C) mRNA expression levels of Batf (A) and Egr2
and Egr3 (C) as measured by RT-PCR, and protein
levels of Batf in nuclear extracts (B) from naive
CD4+ T or B cells from wild-type mice after stim-
ulation with anti-CD3 and anti-CD28 or anti-IgM.
Results in (A) and (C) (mean and SEM) are pre-
sented relative to the expression of b-actin mRNA.
(D) HEK293 cells transfected with Flag-tagged
Egr2 or Flag-tagged Egr2 and Myc-tagged Batf
were lysed. The lysates were used for immuno-
precipitation with anti-Flag-tag or anti-Myc-tag
reagent. The precipitates were immunoblotted
with anti-Myc and anti-Egr2, for anti-Flag precipi-
tates, or with anti-Flag and anti-Batf, for anti-Myc
precipitates. Immunoblotting with anti-Egr2 on
total lysates served as loading controls.
(E) EMSA supershift analysis, using the indicated
antibodies, of nuclear extracts from HEK293 cells
transfected with the indicated genes using the
consensus AP-1 DNA probe.
(F) Coimmunoprecipitation of Egr2 and Batf in CD4
T cells from Egr2 cTg mice after stimulation with
anti-CD3 and anti-CD28 for 16 hr. Data are
representative of two (B, D, and F) or three (A, C,
and E) independent experiments.
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Egr2 and Egr3 Regulate Function of B and T CellsInterestingly, although electrophoretic mobility shift assay
(EMSA) analysis showed a defect in the authentic AP-1
complex bound to the AP-1 DNA probe, an alternative molec-
ular complex, which migrated more quickly than the traditional
AP-1 complex, was detected in the nuclear extracts from Egr2-
and Egr3-deficient, but not wild-type or Egr2 overexpressing, B
and CD4+ T cells (Figures 5A and 5B). The conventional AP-1
complex is a dimer of cFos and Jun. However, the complex
in Egr2- and Egr3-deficient cells was not affected by anti-
cFos, but was effectively supershifted by anti-JunB (Figure 5E).
It has been found recently that Batf, a member of the AP-1
family of transcription factors that is induced in CD4+ T cells
after stimulation, forms a heterodimer with the transcription
factors c-Jun and/or JunB, which binds to the consensus
AP-1 DNA probe and migrates more quickly than the conven-
tional AP-1 complex in EMSA (Macia´n et al., 2001; Schraml
et al., 2009). Batf has multiple functions in the regulation of B
and T cells, including inhibition of AP-1 activation (Quigley
et al., 2010; Williams et al., 2001), inducing Th2 and Th17 cell
derived cytokines (Betz et al., 2010; Schraml et al., 2009),
and regulating T follicular helper (Tfh) cells and B cell function
(Betz et al., 2010; Ise et al., 2011). Therefore, we considered
the possibility that Batf may be part of this alternative AP-1Immunity 37, 685–696,DNA binding complex in Egr2- and
Egr3-deficient B and T cells.
Egr2 Blocks Batf DNA Binding
and Batf Function in Suppression
of AP-1 Activation
To test whether Egr2 is involved in the
regulation of Batf function, we first exam-
ined the expression of Batf in B andT cells. We found that Batf, Egr2, and Egr3 were expressed in
CD44hi T cells (Figure S7B). However, antigen receptor stimula-
tion induced transient expression of Egr2 and Egr3, but a sus-
tained expression of Batf in naive CD4+ T and B cells (Figures
6A–6C). The Batf expression was not influenced by the constitu-
tive expression or absence of Egr2 or Egr3 (Figure S7A), leading
us to conclude that Egr2 and Egr3 do not regulate Batf
transcription.
We next examined the interplay between Batf and Egr2
proteins by cotransfection of these molecules into HEK293 cells
(Figure S7C). We discovered a physical interaction between Batf
and Egr2 (Figure 6D), which blocked the binding of Batf to the
AP-1 DNA probe (Figure 6E). This interaction between Batf and
Egr2 was also detected in CD4+ T cells from Egr2 cTg mice (Fig-
ure 6F). To investigate whether Batf suppresses AP-1 activation
in Egr2- and Egr3-deficient B and T cells, we silenced Batf in
wild-type and Egr2- and Egr3-deficient B and T cells in vitro
(Figures 7A and 7B). We found that silencing of Batf expression
in activated CD4+ T and B cells from CD2-Egr2/Egr3/ mice
restored the activation of AP-1, proliferation, and production of
IL-2 (Figures 7C and 7D). In addition, reduction of Batf expres-
sion reduced the production of the inflammatory cytokine
IL-17A by Egr2- and Egr3-deficient CD4+ T cells (Figure 7E).October 19, 2012 ª2012 Elsevier Inc. 691
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Figure 7. Silencing of Batf in Egr2- and
Egr3-Deficient B and T Cells Restores AP-1
Activation and Proliferative Responses and
Reduces IL-17 Expression
(A and B) CD4+ T or CD19+ B cells from wild-type
(WT) or CD2-Egr2/Egr3/ (K2-3) mice were
transfected with control siRNA (con) or Batf-
specific siRNA (Batf). The transfected cells were
stimulated with anti-CD3 and anti-CD28, for CD4,
or anti-IgM, for CD19 cells, for 16 hr before analysis
of Batf mRNA (A) or protein (B).
(C) Proliferation of, and IL-2 expression by, CD4+ T
or CD19+ B cells fromWT or K2-3mice transfected
with control or Batf siRNA after stimulation with
anti-CD3 and anti-CD28 or anti-IgM for 48 hr.
(D) EMSA analysis of nuclear extracts from control
or Batf siRNA-transfected CD4+ T or CD19+ B cells
from WT or K2-3 mice with the consensus AP-1
DNA probe after stimulation with anti-CD3 and
anti-CD28 for CD4+ T or anti-IgM for CD19+ B cells.
(E) IL-17A mRNA expression by CD4+ T cells
from WT or K2-3 mice transfected with control or
Batf siRNA after stimulation with anti-CD3 and
anti-CD28 for 16 hr. Results in (A) and (E) are
presented relative to the expression of b-actin
mRNA. *p < 0.05 (unpaired Student’s t test). Data
are representative of three (A–C) or two (D–F)
independent experiments.
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Egr2 and Egr3 Regulate Function of B and T CellsTaken together, these findings demonstrate that suppression of
Batf function by Egr2 and/or Egr3 in activated B and T cells is
important for AP-1 activation and the control of IL-17 expression.
DISCUSSION
In this study, we demonstrated that Egr2 and Egr3 have major
regulatory functions in B and T cells for both the control of inflam-
mation and antigen receptor-induced proliferation in a cell-
intrinsic manner. Deficiency in both Egr2 and Egr3 in B and
T cells resulted in lethal inflammatory autoimmune disease.
However, in contrast to other molecules required for the mainte-
nance of immune self-tolerance such as E3 ligases (Bandyopad-
hyay et al., 2007; King et al., 2008; Kitaura et al., 2007; Macia´n
et al., 2002; Puga et al., 2008; Thomas et al., 2007; Zhu and
Paul, 2010), which suppress B and T cell activation by down-
regulation of antigen receptor signaling, Egr2 and Egr3 pro-
moted antigen receptor signaling and proliferation of B and
T cells in response to mitogenic antigen receptor stimulation.
Despite the impaired proliferation and IL-2 production of Egr2-692 Immunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc.and Egr3-deficient B and T cells, antigen
receptor stimulation induced excessive
production of inflammatory cytokines.
These results demonstrate that Egr2
and Egr3 uncouple the proliferation of
naive B and T cells from production of
inflammatory cytokines during mitogenic
antigen stimulation, which may be
important for providing optimal adaptive
immune responses with minimum immu-
nopathology. The transfer of either naive
B or CD4+ T cells from CD2-Egr2/Egr3/ mice into Rag2/ mice resulted in the development of
inflammation in recipient mice demonstrating that Egr2 and
Egr3 function via cell-intrinsic mechanisms to control inflamma-
tory autoimmune responses of both B and T cells.
Egr2 and Egr3 have been found to be involved in the develop-
ment of natural killer T (NKT) cells and thymocytes (Lazarevic
et al., 2009; Xi et al., 2006). We found a reduction of thymocytes
andbonemarrowBcell precursors inCD2-Egr2/Egr3/mice.
However, the subpopulations of mature B and T cells in the
periphery were unchanged. The reduced thymocytes may be
due to defects at the early stages of thymocyte development as
observed for Egr3-deficient thymocytes (Xi et al., 2006). Never-
theless, the defective proliferation and enhanced production of
inflammatory cytokines in wild-type B and T cells after silencing
of Egr2 and Egr3 demonstrate that the developmental defects
in B and T cell precursors are not responsible for the observed
phenotype of lymphocytes from CD2-Egr2/Egr3/ mice.
Egr2 and Egr3 are induced in both naive and tolerant T cells
(Anderson et al., 2006; Harris et al., 2004; Safford et al., 2005).
Silencing of Egr2 in T cells in vitro results in resistance to anergy
Immunity
Egr2 and Egr3 Regulate Function of B and T Cellsinduction (Harris et al., 2004) suggesting that Egr2 and Egr3,
induced in response to TCR stimulation in the absence of costi-
mulatory signals, play important roles in the maintenance of
immune self-tolerance (Harris et al., 2004; Safford et al., 2005).
However, although Egr2- and Egr3-deficient B and T cells in
CD2-Egr2/Egr3/mice were increased in number, displayed
hyperactivated phenotypes, and produced excessive levels of
proinflammatory cytokines, the B and T cells from diseased
mice showed defective responses to antigen receptor stimula-
tion in vitro, with impaired proliferation and defective IL-2
production, suggesting that the induction of autoimmunity in
CD2-Egr2/Egr3/ mice is not due to reduced antigen re-
ceptor activation thresholds, but rather is related to the uncon-
trolled production of inflammatory cytokines and dysregulated
responses to proinflammatory cytokines.
The overproduction of inflammatory cytokines by B and T cells
in CD2-Egr2/Egr3/mice was associated with the hyperacti-
vation of STAT1 and STAT3, the major inflammatory cytokine
pathways controlling the development of Th1 and Th17 cells
and expression of inflammatory cytokines, indicating that Egr2
and Egr3 play important roles in the control of inflammatory
cytokine signaling under homeostatic conditions. We have
demonstrated that Egr2 and Egr3 directly regulated SOCS1
and SOCS3 expression and deficiency in Egr2 and Egr3 resulted
in reduced expression of SOCS1 and SOCS3. SOCS1 and
SOCS3 are essential regulators for the control of STAT1- and
STAT3-mediated cytokine expression and differentiation of Th1
and Th17 cells (Tamiya et al., 2011).
Deficiency in SOCS1 results in severe lymphopenia, activation
of peripheral T cells, and multiorgan inflammation resulting in
death at an early age (Marine et al., 1999). SOCS1 deficient
T cells are hypersensitive to multiple cytokines resulting in
IFN-g production in the absence of TCR ligation (Chong et al.,
2005). SOCS3 is essential for the control of Th17 cell differentia-
tion by desensitizing STAT3 to activating cytokines, such as
IL-23, thereby controlling the expression of Th17 cell-derived
cytokines (Chen et al., 2006; Tanaka et al., 2008). Deficiency of
SOCS1 or SOCS3 specifically in lymphoid and myeloid cells
results in the development of inflammatory diseases (Chong
et al., 2005; Croker et al., 2004). However, although deficiency
of SOCS1 specifically in T cells results in increased IFN-g
production and enhanced development of Th1 cells, the mice
do not develop spontaneous inflammatory pathologies and
SOCS1 deficient T cells are resistant to Th17 cell differentiation
(Tanaka et al., 2008). A T cell specific SOCS3 defect renders
the cells more susceptible to Th17 cell differentiation, but also
increases IL-10 production and reduces Th1 cell polarization
(Taleb et al., 2009). These findings suggest that inflammatory
pathology, which normally results from pathological functions
of both Th1 and Th17 cell-derived cytokines, is controlled by
both SOCS1 and SOCS3. We have now demonstrated that
both SOCS1 andSOCS3 are induced in B and T cells in response
to antigen receptor stimulation. Although we cannot rule out
additional mechanisms contributing to the lethal inflammatory
autoimmune responses in CD2-Egr2/Egr3/ mice, the ex-
cessive production of Th1 and Th17 cell-derived cytokines and
activation of STAT1 and STAT3 in Egr2- and Egr3-deficient B
and T cells suggest that regulation of SOCS1 and SOCS3
expression by Egr2 and Egr3 is vital, not only for preventingthe development of autoimmune diseases, but also for limiting
immunopathology during productive adaptive immune re-
sponses. Previously, we found that Egr2 regulates expression
of p21CIP1 (Zhu et al., 2008), which was supported by a recent
study (Pospisil et al., 2011). Although the expression of p21CIP1
is also reduced in Egr2- and Egr3-deficient CD4+ T cells after
T cell receptor stimulation, the level of reduction is similar to
that in CD4+ T cells deficient in Egr2 alone, suggesting that the
severe early-onset inflammatory autoimmunity in CD2-Egr2/
Egr3/ mice is not due to decreased expression of p21CIP1.
An important, but unexpected, function of Egr2 and Egr3 is the
positive regulation of antigen receptor-induced proliferation.
Egr2 and Egr3 have previously been considered to be negative
regulators of T cell receptor signaling and T cell activation that
function to induce expression of E3 ligases, leading to degrada-
tion of T cell receptor signaling molecules (Harris et al., 2004;
Safford et al., 2005). However, naive T cells lacking either Egr2
or Egr3 did not show increased activation in response to antigen
receptor stimulation (Zhu et al., 2008. In contrast, deficiency in
both Egr2 and Egr3 resulted in impaired proliferation of naive B
and T cells in response to antigen receptor stimulation. Collec-
tively, these data suggest that Egr2 and Egr3 may play different
roles in naive and anergic T cells. In anergic T cells, MAP kinase,
AP-1, and NF-kB are suppressed while NFAT is activated
because of partial antigen receptor stimulation. Therefore,
suppression of Batf by Egr2 and Egr3 in anergic T cells does
not enhance AP-1 activity; instead, Egr2 and Egr3 function to
maintain the tolerance of anergic T cells by induction of E3
ligases (Harris et al., 2004; Safford et al., 2005).
We have now demonstrated that Egr2 and Egr3 have an over-
lapping function that is required for the induction of AP-1 activity
in B and T cells in response to antigen receptor stimulation,
which is mediated by directly blocking the function of Batf,
a suppressor of AP-1 (Quigley et al., 2010; Williams et al.,
2001). In addition to restoring AP-1 activity and proliferative
responses, silencing of Batf in Egr2- and Egr3-deficient CD4+
T cells also reduced expression of IL-17, consistent with
previous findings on the role of Batf in IL-17 expression (Betz
et al., 2010; Schraml et al., 2009), suggesting that suppression
of Batf function by Egr2 and/or Egr3 also contributes to the
control of inflammatory pathology.
The expression of Egr2 and Egr3 in resting B and T cells
induced by antigen receptor stimulation was transient, whereas
Batf expression was sustained for much longer. The differential
expression kinetics of Egr2 and Egr3 and Batf implies a model
in which the transient repression of Batf function by Egr2 and
Egr3 only occurs at the early stages of antigen-mediated
responses, thus allowing the expansion of activated B and
T cells, whereas the subsequent rapid cessation of Egr2 and
Egr3 expression leads to the restoration of Batf function, thereby
facilitating the production of antibodies and effector cytokines.
Recently, it has been reported that deletion of JunB and/or
c-Jun specifically in epithelial cells results in skin inflammation
leading to a systemic lupus erythematosus (SLE)-like syndrome
with increased expression of serum proinflammatory cytokines
and a myeloproliferation disorder (Guinea-Viniegra et al., 2009;
Meixner et al., 2008; Pflegerl et al., 2009; Zenz et al., 2005), sug-
gesting that normal and controlled AP-1 activity under homeo-
static conditions is important for preventing inflammation andImmunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc. 693
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Egr2 and Egr3 Regulate Function of B and T Cellsmaintaining skin homeostasis. In addition to our previous finding
of Egr2 expression in CD44hi effector phenotype T cells (Zhu
et al., 2008), Egr-3 is also expressed in CD44hi T cells under
homeostatic conditions, Whether the function of c-Jun and/or
JunB is regulated by Egr2 and/or Egr3 in effector phenotype
lymphocytes in response to homeostatic stimulation and, if so,
the importance of this for the control of inflammatory cytokine
expression in B and T cells has yet to be investigated.
The impaired antigen receptor-induced proliferation in vitro
but inflammatory activity in vivo discovered in Egr2- and Egr3-
deficient B and T cells resemble the findings from B and T cells
in both lupus patients and lupus models, which show hyperin-
flammatory activity in vivo and yet defective AP-1 activation
and IL-2 expression in vitro (Crispı´n et al., 2011; Jenks and
Sanz, 2009; Rauen et al., 2011), supporting the notion that dys-
regulation of Egr2 and Egr3, reported recently in both lupus
models and lupus patients (Myouzen et al., 2010; Sela et al.,
2008), may play a part in the development of lupus-like systemic
autoimmune diseases. Our results uncover an intrinsic regula-
tory mechanism mediated by Egr2 and Egr3 in both B and
T cells for the regulation of immune homeostasis and antigen-
specific immune responses.
EXPERIMENTAL PROCEDURES
Mice
Egr3/ and CD2-specific Egr2/ (CD2-Egr2/Egr3/) mice were gener-
ated by interbreeding Egr3/ (Tourtellotte and Milbrandt, 1998) and CD2-
specific Egr2/ mice (Zhu et al., 2008) on the C57BL/6 background. All
mice were maintained in the Animal Unit, Brunel University, and used in accor-
dance with established guidelines of institutional ethical committee under the
authority of a UK Home Office project license (Guidance on the Operation of
Animals, Scientific Procedures Act 1986).
Proliferation
For measuring proliferation, purified CD4+ T or B cells (5 3 104 cells/200 ml) in
96-well plates were stimulated in triplicate. A total of 1 mCi of [3H]TdR was
added for the last 8 hr of culture, and the cells were then harvested and sub-
jected to scintillation counting tomeasure [3H]TdR incorporation. Alternatively,
a total of 10 uMBrdUwas added for the last hour of culture, and cells were then
harvested and stained with PE-conjugated anti-BrdU antibody and 7AAD with
the BrdU flow kit (BD Biosciences). The percentage of T cells that had incorpo-
rated BrdU was analyzed by flow cytometry.
EMSA
The consensus probes for AP-1 (50-AGCTTCGCTTGATGAGTCAGCCG-30),
NFkB (50-CAGAGGGGACTTTCCGAGA-30), SP1 (50-ATTCGATCGGGGCGG
GGCCAG-30), and NFAT (50- CTGTATCAAACAAATTTTCCTCTTTGG-30 ) were
labeled with [a-32P]dCTP using Ready-to-Go DNA labeling beads (Amersham
Biosciences UK Ltd., Pollards Wood, Bucks) and used in binding reactions
with nuclear extracts from lymphocytes stimulated with anti-CD3 and anti-
CD28, for CD4+ T cells, or anti-IgM, for B cells, for 24 hr, and then restimulated
for 30 min (Zhu et al., 2008). For supershift reactions anti-Myc, anti-cFos and
anti-JunB were added after 10 min of incubation. The samples were electro-
phoresed on 5% polyacrylamide gels in 0.53 TBE. The gels were processed
and then exposed to X-ray film or analyzed on a Storm 860 PhosphorImager
(Molecular Dynamics). The intensity of the AP-1 band was normalized relative
to the activity of SP1.
ChIP Assays
ChIP assays were performed in accordance with the protocol supplied with
the Kit (cat 9003) from Cell Signaling Technology. In brief, 5 3 107 CD4+
T cells from Egr2 cTg mice were stimulated with anti-CD3 and anti-CD28
for 3 hr. The cells were then crosslinked with 1% formaldehyde for 10 min694 Immunity 37, 685–696, October 19, 2012 ª2012 Elsevier Inc.at room temp. After quenching of formaldehyde with 125 mM glycine,
the cell nuclei were collected for nuclease digestion. The fragmented
chromatin was 300–1000 bp as analyzed on agarose gels. After preclearing,
chromatin (500 mg) was subjected to each immunoprecipitation with
specific anti-Egr2 Ab (Covance) or anti-histone 3 Ab as positive control or
anti-Ig as negative control at 4C overnight. Immunocomplexes were
recovered by incubation with blocked protein A beads. DNA was purified in
accordance with the kit and used as template for PCR with specific primers
SOCS1 (Chr 16, 7786214 –7786320) sense (50-CTTCAAAGGAAGCCTAA
GGCG-30) and antisense (50-CCACGTAGTAAGAGTGCAGAG-30), SOCS3-1
(Chr 11, 29364759 –29364951) sense (50-CAAGGATTTCACAAACGCCTG-30)
and antisense (50-GAGAGGCCTGTAGTACACCA-30), SOCS3-2 (Chr 11,
29371868 –29372072) sense (50-CCAACTTCTCATTCACACTTTCC-30) and
antisense (50-TACATGAGGACCTCGGAGTG-30), and Nab2 sense (50-ATAGC
TCGGCCTCGGTCAC-30) and antisense (50-GGACTCAAGAATCGGGCTC-30 ).
Messenger RNA Silencing
Specific short interfering oligonucleotides (siRNA) against the mRNA
sequence of BATF, Egr2 and Egr3: siBatf 2, 50-GAACGCAGCUCUCCG
CAAA-30; siBatf 4, 50-GGACUCAUCUGAUGAUGUG-30, siEgr2-1, GCUGCU
AUCCAGAAGGUAU-30; siEgr2-2, 50-CGACCUCGAAAGUACCCUA-30, and
siEgr3-1, 50-GCGACUCGGUAGCCCAUUA-30; and siEgr3-2, 50-GCAGUUU
GCUAAAUCAAUU-30, were used. Irrelevant scrambled siRNAs obtained
from QIAGEN, CAT: 1027281, were used as negative controls. Primary naive
CD4+ T and resting B cells isolated from 4-week-old mice were transfected
with an Amaxa Nucleofector in accordance with the manufacturer’s instruc-
tions with 1 mM siRNA and assayed no more than 72 hr later. The Batf
siRNAs sustained specific reductions in Batf expression for at least 72 hr, as
monitored by RT-PCR, with BATF siRNA2 more effective than BATF siRNA4.
Therefore, BATF siRNA2 was used throughout this study.
Adoptive Transfer
A total of 106 naive CD4+ T or resting B cells from 4-week-old mice were
suspended in 100 ml of physiological saline and injected i.v. into the dorsal
tail vein of female Rag2/ mice at 12 weeks of age. Two or six weeks after
transfer, CD4+ T and B cells were isolated from the spleen, and serum anti-
bodies and cytokines were measured.
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